APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis B Vaccines

Hepatitis B vaccine is a vaccine that prevents hepatitis B.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hepatitis B vaccine is a vaccine that prevents hepatitis B.

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis B Vaccines Market Outlook and Growth Opportunities 2026

28 December 2025195 pages

Choose your research edition.

Industry ResearchHepatitis B Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis B Vaccines Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Hepatitis B Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis B Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis B Vaccines Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

Hepatitis B vaccine is a vaccine that prevents hepatitis B.

In the last several years, Global market of Hepatitis B vaccine developed smoothly, with an average growth rate of -0.32%.

The classification of Hepatitis B vaccine includes Yeast Derived, CHO Derived, and the sales proportion of Yeast Derived in 2019 is about 97%. Hepatitis B vaccine is widely used for Children and Adult. About 84% of Hepatitis B vaccine is used for Children.

Read the full market overview

Asia-Pacific is the largest consumption place, with a consumption market share nearly 50% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of nearly 30%.

Market competition is intense. GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

This report provides an overview of the global Hepatitis B Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis B Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis B Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis B Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatitis B Vaccines Segment by Company

GSK

NCPC

Merck

Bio Kangtai

Dynavax

Hissen

KM Biologics

LG Life Sciences

Serum Institute

Hepatitis B Vaccines Segment by Type

Yeast Derived

CHO Derived

Hepatitis B Vaccines Segment by Application

Children

Adult

Hepatitis B Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hepatitis B Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatitis B Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis B Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis B Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis B Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis B Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis B Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatitis B Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis B Vaccines industry.

Chapter 3: Detailed analysis of Hepatitis B Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatitis B Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatitis B Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis B Vaccines Industry Trends Table 2. Hepatitis B Vaccines Industry Drivers Table 3. Hepatitis B Vaccines Industry Opportunities and Challenges Table 4. Hepatitis B Vaccines Industry Restraints Table 5. Global Hepatitis B Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis B Vaccines Revenue Share by Company (2021-2026) Table 7. Global Hepatitis B Vaccines Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Hepatitis B Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Hepatitis B Vaccines Average Price (USD/Doses) of Company (2021-2026) Table 10. Global Hepatitis B Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatitis B Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Hepatitis B Vaccines Company, Product Type & Application Table 13. Global Hepatitis B Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatitis B Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Yeast Derived Table 18. Significant Companies of CHO Derived Table 19. Global Hepatitis B Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 20. Global Hepatitis B Vaccines Sales Volume by Type (2021-2026) & (M Doses) Table 21. Global Hepatitis B Vaccines Sales Volume by Type (2027-2032) & (M Doses) Table 22. Global Hepatitis B Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Hepatitis B Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Hepatitis B Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatitis B Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatitis B Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatitis B Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Hepatitis B Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Children Table 30. Significant Companies of Adult Table 31. Global Hepatitis B Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 32. Global Hepatitis B Vaccines Sales Volume by Application (2021-2026) & (M Doses) Table 33. Global Hepatitis B Vaccines Sales Volume by Application (2027-2032) & (M Doses) Table 34. Global Hepatitis B Vaccines Sales Volume Share by Application (2021-2026) Table 35. Global Hepatitis B Vaccines Sales Volume Share by Application (2027-2032) Table 36. Global Hepatitis B Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Hepatitis B Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Hepatitis B Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Hepatitis B Vaccines Sales Value Share by Application (2021-2026) Table 40. Global Hepatitis B Vaccines Sales Value Share by Application (2027-2032) Table 41. Global Hepatitis B Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 42. Global Hepatitis B Vaccines Sales by Region (2021-2026) & (M Doses) Table 43. Global Hepatitis B Vaccines Sales Market Share by Region (2021-2026) Table 44. Global Hepatitis B Vaccines Sales by Region (2027-2032) & (M Doses) Table 45. Global Hepatitis B Vaccines Sales Market Share by Region (2027-2032) Table 46. Global Hepatitis B Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Hepatitis B Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Hepatitis B Vaccines Sales Value Share by Region (2021-2026) Table 49. Global Hepatitis B Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Hepatitis B Vaccines Sales Value Share by Region (2027-2032) Table 51. Global Hepatitis B Vaccines Market Average Price (USD/Doses) by Region (2021-2026) Table 52. Global Hepatitis B Vaccines Market Average Price (USD/Doses) by Region (2027-2032) Table 53. Global Hepatitis B Vaccines Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 54. Global Hepatitis B Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Hepatitis B Vaccines Sales by Country (2021-2026) & (M Doses) Table 56. Global Hepatitis B Vaccines Sales Market Share by Country (2021-2026) Table 57. Global Hepatitis B Vaccines Sales by Country (2027-2032) & (M Doses) Table 58. Global Hepatitis B Vaccines Sales Market Share by Country (2027-2032) Table 59. Global Hepatitis B Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Hepatitis B Vaccines Sales Value Market Share by Country (2021-2026) Table 61. Global Hepatitis B Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Hepatitis B Vaccines Sales Value Market Share by Country (2027-2032) Table 63. GSK Company Information Table 64. GSK Business Overview Table 65. GSK Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 66. GSK Hepatitis B Vaccines Product Portfolio Table 67. GSK Recent Development Table 68. NCPC Company Information Table 69. NCPC Business Overview Table 70. NCPC Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 71. NCPC Hepatitis B Vaccines Product Portfolio Table 72. NCPC Recent Development Table 73. Merck Company Information Table 74. Merck Business Overview Table 75. Merck Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 76. Merck Hepatitis B Vaccines Product Portfolio Table 77. Merck Recent Development Table 78. Bio Kangtai Company Information Table 79. Bio Kangtai Business Overview Table 80. Bio Kangtai Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 81. Bio Kangtai Hepatitis B Vaccines Product Portfolio Table 82. Bio Kangtai Recent Development Table 83. Dynavax Company Information Table 84. Dynavax Business Overview Table 85. Dynavax Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 86. Dynavax Hepatitis B Vaccines Product Portfolio Table 87. Dynavax Recent Development Table 88. Hissen Company Information Table 89. Hissen Business Overview Table 90. Hissen Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 91. Hissen Hepatitis B Vaccines Product Portfolio Table 92. Hissen Recent Development Table 93. KM Biologics Company Information Table 94. KM Biologics Business Overview Table 95. KM Biologics Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 96. KM Biologics Hepatitis B Vaccines Product Portfolio Table 97. KM Biologics Recent Development Table 98. LG Life Sciences Company Information Table 99. LG Life Sciences Business Overview Table 100. LG Life Sciences Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 101. LG Life Sciences Hepatitis B Vaccines Product Portfolio Table 102. LG Life Sciences Recent Development Table 103. Serum Institute Company Information Table 104. Serum Institute Business Overview Table 105. Serum Institute Hepatitis B Vaccines Sales (M Doses), Value (US$ Million), Price (USD/Doses) and Gross Margin (2021-2026) Table 106. Serum Institute Hepatitis B Vaccines Product Portfolio Table 107. Serum Institute Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Hepatitis B Vaccines Distributors List Table 111. Hepatitis B Vaccines Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Hepatitis B Vaccines Product Image Figure 2. Global Hepatitis B Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis B Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatitis B Vaccines Sales (2021-2032) & (M Doses) Figure 5. Global Hepatitis B Vaccines Sales Average Price (USD/Doses) & (2021-2032) Figure 6. Global Hepatitis B Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Yeast Derived Image Figure 10. CHO Derived Image Figure 11. Global Hepatitis B Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 12. Global Hepatitis B Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatitis B Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatitis B Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatitis B Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatitis B Vaccines Sales Value Share by Type (2021-2032) Figure 17. Children Image Figure 18. Adult Image Figure 19. Global Hepatitis B Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 20. Global Hepatitis B Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Hepatitis B Vaccines Sales Volume Share by Application (2021-2032) Figure 22. Global Hepatitis B Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hepatitis B Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Hepatitis B Vaccines Sales Value Share by Application (2021-2032) Figure 25. Global Hepatitis B Vaccines Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 26. Global Hepatitis B Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Hepatitis B Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Hepatitis B Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Hepatitis B Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. North America Hepatitis B Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Hepatitis B Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Hepatitis B Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Hepatitis B Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Hepatitis B Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Hepatitis B Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. South America Hepatitis B Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Hepatitis B Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Hepatitis B Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Hepatitis B Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Hepatitis B Vaccines Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Hepatitis B Vaccines Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Yeast Derived
  • CHO Derived
Applications
  • Children
  • Adult
Companies covered
  • GSK
  • NCPC
  • Merck
  • Bio Kangtai
  • Dynavax
  • Hissen
  • KM Biologics
  • LG Life Sciences
  • Serum Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis B Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Hepatitis B Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatitis B Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatitis B Vaccines Market Dynamics
  1. 2.1 Hepatitis B Vaccines Industry Trends
  2. 2.2 Hepatitis B Vaccines Industry Drivers
  3. 2.3 Hepatitis B Vaccines Industry Opportunities and Challenges
  4. 2.4 Hepatitis B Vaccines Industry Restraints
3 Hepatitis B Vaccines Market by Company
  1. 3.1 Global Hepatitis B Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis B Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis B Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatitis B Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Hepatitis B Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Hepatitis B Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatitis B Vaccines Company Product Type and Application
  8. 3.8 Global Hepatitis B Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatitis B Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatitis B Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatitis B Vaccines Market by Type
  1. 4.1 Hepatitis B Vaccines Type Introduction
  2. 4.1.1 Yeast Derived
  3. 4.1.2 CHO Derived
  4. 4.2 Global Hepatitis B Vaccines Sales Volume by Type
  5. 4.2.1 Global Hepatitis B Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatitis B Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatitis B Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatitis B Vaccines Sales Value by Type
  9. 4.3.1 Global Hepatitis B Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatitis B Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatitis B Vaccines Sales Value Share by Type (2021-2032)
5 Hepatitis B Vaccines Market by Application
  1. 5.1 Hepatitis B Vaccines Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Hepatitis B Vaccines Sales Volume by Application
  5. 5.2.1 Global Hepatitis B Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Hepatitis B Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Hepatitis B Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Hepatitis B Vaccines Sales Value by Application
  9. 5.3.1 Global Hepatitis B Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Hepatitis B Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Hepatitis B Vaccines Sales Value Share by Application (2021-2032)
6 Hepatitis B Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Hepatitis B Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis B Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatitis B Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatitis B Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Hepatitis B Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatitis B Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatitis B Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatitis B Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatitis B Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatitis B Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Hepatitis B Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatitis B Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatitis B Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatitis B Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatitis B Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatitis B Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Hepatitis B Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatitis B Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatitis B Vaccines Sales Value Share by Country, 2025 VS 2032
7 Hepatitis B Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Hepatitis B Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis B Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatitis B Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatitis B Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatitis B Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Hepatitis B Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatitis B Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatitis B Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatitis B Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatitis B Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatitis B Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Hepatitis B Vaccines Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 NCPC
  8. 8.2.1 NCPC Company Information
  9. 8.2.2 NCPC Business Overview
  10. 8.2.3 NCPC Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 NCPC Hepatitis B Vaccines Product Portfolio
  12. 8.2.5 NCPC Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Hepatitis B Vaccines Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Bio Kangtai
  20. 8.4.1 Bio Kangtai Company Information
  21. 8.4.2 Bio Kangtai Business Overview
  22. 8.4.3 Bio Kangtai Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bio Kangtai Hepatitis B Vaccines Product Portfolio
  24. 8.4.5 Bio Kangtai Recent Developments
  25. 8.5 Dynavax
  26. 8.5.1 Dynavax Company Information
  27. 8.5.2 Dynavax Business Overview
  28. 8.5.3 Dynavax Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Dynavax Hepatitis B Vaccines Product Portfolio
  30. 8.5.5 Dynavax Recent Developments
  31. 8.6 Hissen
  32. 8.6.1 Hissen Company Information
  33. 8.6.2 Hissen Business Overview
  34. 8.6.3 Hissen Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hissen Hepatitis B Vaccines Product Portfolio
  36. 8.6.5 Hissen Recent Developments
  37. 8.7 KM Biologics
  38. 8.7.1 KM Biologics Company Information
  39. 8.7.2 KM Biologics Business Overview
  40. 8.7.3 KM Biologics Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 KM Biologics Hepatitis B Vaccines Product Portfolio
  42. 8.7.5 KM Biologics Recent Developments
  43. 8.8 LG Life Sciences
  44. 8.8.1 LG Life Sciences Company Information
  45. 8.8.2 LG Life Sciences Business Overview
  46. 8.8.3 LG Life Sciences Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 LG Life Sciences Hepatitis B Vaccines Product Portfolio
  48. 8.8.5 LG Life Sciences Recent Developments
  49. 8.9 Serum Institute
  50. 8.9.1 Serum Institute Company Information
  51. 8.9.2 Serum Institute Business Overview
  52. 8.9.3 Serum Institute Hepatitis B Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Serum Institute Hepatitis B Vaccines Product Portfolio
  54. 8.9.5 Serum Institute Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatitis B Vaccines Value Chain Analysis
  2. 9.1.1 Hepatitis B Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatitis B Vaccines Sales Mode & Process
  6. 9.2 Hepatitis B Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatitis B Vaccines Distributors
  9. 9.2.3 Hepatitis B Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst